4d Pharma PLC Director/PDMR Shareholding (7664Z)
22 Maggio 2019 - 8:01AM
UK Regulatory
TIDMDDDD
RNS Number : 7664Z
4d Pharma PLC
22 May 2019
The information contained within this announcement is deemed by
the Company to constitute inside information stipulated under the
Market Abuse Regulation (EU) No. 596/2014. Upon the publication of
this announcement via the Regulatory Information Service, this
inside information is now considered to be in the public
domain.
4D pharma plc
(the "Company" or "4D")
PDMR Dealings
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the
development of Live Biotherapeutics, is pleased to announce that
David Norwood, Duncan Peyton and Alex Stevenson (the "Directors")
have purchased ordinary shares in the Company as listed below.
Following this transaction, the Directors have a resulting interest
in the ordinary shares of the Company as listed below.
Name Shares in % of total Shares in % of total
4D pharma shares in 4D pharma shares in
plc before issue plc after issue
purchase purchase
David Norwood (Chairman) 7,103,725 10.85% 7,108,725 10.85%
Duncan Peyton (CEO) 6,343,985 9.69% 6,445,184 9.84%
Alex Stevenson (CSO) 6,362,138 9.71% 6,413,136 9.79%
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name David Norwood
------------------------------ --------------------------------
2 Reason for the notification
----------------------------------------------------------------
a) Position/status PDMR
------------------------------ --------------------------------
b) Initial notification Initial notification
/Amendment
------------------------------ --------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------
a) Name 4D Pharma plc
------------------------------ --------------------------------
b) LEI 213800O49VYSXWE2ZD52
------------------------------ --------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------
a) Description of the Ordinary shares of GBP0.0025
financial instrument, ISIN: GB00BJL5BR07
type of instrument
Identification code
------------------------------ --------------------------------
b) Nature of the transaction Purchase of Ordinary Shares
------------------------------ --------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
96p 5,000
----------
------------------------------ --------------------------------
d) Aggregated information
- Aggregated volume N/A
- Price
------------------------------ --------------------------------
e) Date of the transaction 21(st) May 2019
------------------------------ --------------------------------
f) Place of the transaction London Stock Exchange, AIM
------------------------------ --------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Duncan Peyton
-------------------------- --------------------------------------
2 Reason for the notification
------------------------------------------------------------------
a) Position/status PDMR
-------------------------- --------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------- --------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------
a) Name 4D Pharma plc
-------------------------- --------------------------------------
b) LEI 213800O49VYSXWE2ZD52
-------------------------- --------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------------------------------------------------------------------
a) Description of the Ordinary shares of GBP0.0025
financial instrument, ISIN: GB00BJL5BR07
type of instrument
Identification code
-------------------------- --------------------------------------
b) Nature of the transaction Purchase of Ordinary Shares
-------------------------- --------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
99.4p 101,199
----------
-------------------------- --------------------------------------
d) Aggregated information
- Aggregated volume N/A
- Price
-------------------------- --------------------------------------
e) Date of the transaction 21(st) May 2019
-------------------------- --------------------------------------
f) Place of the transaction London Stock Exchange, AIM
-------------------------- --------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Alex Stevenson
-------------------------- --------------------------------------
2 Reason for the notification
------------------------------------------------------------------
a) Position/status PDMR
-------------------------- --------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------- --------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------
a) Name 4D Pharma plc
-------------------------- --------------------------------------
b) LEI 213800O49VYSXWE2ZD52
-------------------------- --------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------------------------------------------------------------------
a) Description of the Ordinary shares of GBP0.0025
financial instrument, ISIN: GB00BJL5BR07
type of instrument
Identification code
-------------------------- --------------------------------------
b) Nature of the transaction Purchase of Ordinary Shares
-------------------------- --------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
98p 50,998
----------
-------------------------- --------------------------------------
d) Aggregated information
- Aggregated volume N/A
- Price
-------------------------- --------------------------------------
e) Date of the transaction 21(st) May 2019
-------------------------- --------------------------------------
f) Place of the transaction London Stock Exchange, AIM
-------------------------- --------------------------------------
For further information please contact:
4D
Duncan Peyton, Chief Executive Officer + 44 (0)113 895 0130
Fay Weston, Head of Investor Relations + 44 (0)7990 381713
Zeus Capital Limited - Nomad and Joint Broker +44 (0)161 831 1512
Dan Bate / Jordan Warburton
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500
Dominic Wilson
Phil Walker
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHEAXSFAAFNEFF
(END) Dow Jones Newswires
May 22, 2019 02:01 ET (06:01 GMT)
Grafico Azioni 4d Pharma (LSE:DDDD)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni 4d Pharma (LSE:DDDD)
Storico
Da Apr 2023 a Apr 2024
